[Drug therapy's new options in the treatment of the severe irritable bowel syndrome].

A A Viaznikova I N Ruchkina G M Diukova N V Romashkina L K Indejkina D A Degterev A I Parfenov

Published in: Terapevticheskii arkhiv (2023)

The severe course of IBS-D is mainly associated with the patients' individual characteristics and anxiety or anxiety-depressive syndromes. The positive impact of duloxetine therapy in severe IBS-D with extraintestinal manifestations is associated with the regulation of serotonergic and noradrenergic activity of the central.

Keyphrases

irritable bowel syndrome
early onset
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
drug induced
sleep quality
bipolar disorder
stem cells
physical activity
bone marrow
stress induced
cell therapy
patient reported
replacement therapy